<DOC>
	<DOCNO>NCT01155037</DOCNO>
	<brief_summary>This randomize , open label , phase II trial evaluate safety immunogenicity two different schedule vaccination influenza A H1N1 HIV-infected individual , randomize group compare HIV-negative volunteer vaccinate regimen indicate Brazilian National Immunization Program . Will include study HIV-infected patient , stratify CD4 count ( &lt; 200 cells/mm3 &gt; 200 cells/mm3 ) time screen study , receive antiretroviral therapy treatment receive stable treatment least 8 week , plan change next 6 month , eligible receive vaccine influenza A H1N1 . The control group form HIV-negative individual , confirm serology perform screening , eligible receive vaccine influenza A H1N1 . Patients infected HIV receive one two possible vaccination regimen : 1 ) 3.75 µg two application 21 day apart , 2 ) 7.5 µg two application 21 day apart . The volunteer control group receive single application 3.75 µg dose vaccine . The study 's hypothesis : 1 ) The vaccine H1N1 virus promote antibody titer level specify protection ( seroconversion ) , safe well tolerated patient HIV-1 infect non HIV-infected volunteer ; 2 ) The proportion seroconversion H1N1 virus vaccine dose 3.75 µg HIV-1-infected patient similar proportion seroconversion induce vaccine dose 7.5 µg ; 3 ) The proportion seroconversion one dose vaccine H1N1 virus similar proportion second dose .</brief_summary>
	<brief_title>Safety Immunogenicity H1N1 Influenza Vaccine HIV-infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria participant Both gender , age 18 59 year ; Capacity give inform consent voluntarily participate study ; Study participant reproductive potential ( defined girl menarche woman reach menopause least 24 consecutive month , menstruate past 24 month , undergone surgical sterilization ) must pregnancy test negative result , blood urine , screen vaccine application day . If sexual practice likely promote pregnancy , participant must use form contraception study period . At least one follow method MUST properly use : Condoms ( male female , Hormonal contraceptive . Laboratory result study screen : hemoglobin &gt; 8.0 g/dL ; Direct bilirubin &lt; 2.5 x upper limit normal ; Alanine aminotransferase , ALT ( SGPT ) aspartate aminotransferase , AST ( SGOT ) &lt; 3 x upper limit normal ; Platelet count &gt; 100.000/mm3 Inclusion Criteria unique participant HIV infection : HIV1 infection ( evidence rapid HIV test ELISA kit approve confirmed repeat ELISA , IFA , Western blot , HIV1 plasma viral load ) time enter study . Without change antiretroviral treatment within 8 week prior screen study : If volunteer receive HAART he/she require use regimen within least 8 week screen . Changes antiretroviral dosage within 8 week prior enter study permit . In addition , exchange pharmacological formulation ( eg . conventional formulation combination formulation ) allow . If volunteer regular antiretroviral treatment , he/she receive dose antiretroviral within 8 week prior screen , include prevention HIV vertical transmission ( previous prophylactic therapeutic regimen allow ) Without plan change start HAART next 6 month . Inclusion criterion unique participant without HIV infection ( control group ) : HIVnegative test result document rapid test approve Brazil Health professional indication receive H1N1 virus vaccine Use systemic anticancer immunomodulator treatment , corticosteroid , experimental vaccine , interleukin , interferon , growth factor intravenous immunoglobulin ( IVIG ) within 45 day prior entry study . Pregnancy lactation . Allergy and/or sensitivity know hypersensitivity residue present vaccine ( egg , chicken protein , egg albumin , formaldehyde , gentamicin sulphate sodium deoxycholate ) and/or thimerosal . Use alcohol addiction condition opinion site 's investigator , may interfere compliance study requirement . D5 . Serious illness require systemic treatment and/or hospitalization within 45 day prior entry study Severe febrile illness acute infection time screen study and/or day vaccination Vaccination seasonal influenza last 12 month prior study entry Previous vaccination influenza A H1N1 History family history GuillainBarré Syndrome ( parent , sibling , halfsiblings child ) . Diagnosis neurological condition include ( limited ) absence deep tendon reflex , Achilles patellar , leg ( four miss ) last six month . Disproportionate force loss lower limb ( ) compare upper limb last six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HIV , influenza A H1N1 , vaccine</keyword>
</DOC>